Selexipag (NS-304; NS304; ACT-293987; ACT293987; Uptravi) is a novel and potent prodrug of ACT-333679 (MRE-269) acting as non-prostanoid IP receptor agonist and has been approved as a medication for the treatment of pulmonary arterial hypertension.

Asapiprant (S555739) is a novel, potent and selective Prostaglandin D2receptor 1 (DP1) receptor antagonist (Ki = 0.44 nM) with the potential for treating allergic airway diseases.

Seratrodast (AA-2414) is a novel, potent and selective thromboxane A2 (TXA2) receptor (TP receptor) antagonist used mainlyin the treatment of asthma.

Laropiprant (aslo known as MK-0524; Cordaptive) is a novel, potent, selective DP [prostaglandin D2 (PGD2) receptor (DP)] receptor antagonist with Ki values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.

Grapiprant (formerly known as CJ-023,423, RQ-00000007, or AAT-007) is a selective and potent EP4 receptor antagonist.

Treprostinil (LRX-15; trade names: Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation), a synthetic analog of prostacyclin (PGI2), is a novel and potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.

Iloprost (Ciloprost; ZK-36374; Trade names: Ventavis, Ilomedine), a novel potent synthetic analog of prostacyclin PGI2, is an approved drug used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud’s phenomenon and other diseases in which the blood vessels are constricted and blood can’t flow to the tissues.

MK-2894 is a novel, potent and selective antagonist of prostaglandin E2 subtype 4 receptor (PGE2).

GW627368 (also known as GW-627368; GW-627368X) is a novel, orally bioavailable, potent and selective competitive antagonist of prostanoid EP4 receptor with anticancer activity.

NTP42 is a novel thromboxane A2 (TXA2) receptor antagonist with an IC50 of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca2+] mobilization following stimulation of cells with the alternative TP agonist U46609.